key: cord-0744423-jczelgpz
authors: Begum, Mst. Noorjahan; Jubair, Mohammad; Nahar, Kamrun; Rahman, Sezanur; Talha, Muhammad; Sarker, Md Safiullah; Uddin, A K M Nasir; Khaled, Saifuddin; Uddin, Mohammed Shehab; Li, Zhibiao; Ke, Tianlin; Rahman, Mohammed Ziaur; Rahman, Mustafizur
title: Factors influencing the performance of rapid SARS‐CoV‐2 antigen tests under field condition
date: 2021-12-23
journal: J Clin Lab Anal
DOI: 10.1002/jcla.24203
sha: f8aa54c46456af5bffdd59da72d7a24693d9a86d
doc_id: 744423
cord_uid: jczelgpz

BACKGROUND: Globally, real‐time reverse transcription–polymerase chain reaction (rRT‐PCR) is the reference detection technique for SARS‐CoV‐2, which is expensive, time consuming, and requires trained laboratory personnel. Thus, a cost‐effective, rapid antigen test is urgently needed. This study evaluated the performance of the rapid antigen tests (RATs) for SARS‐CoV‐2 compared with rRT‐PCR, considering different influencing factors. METHODS: We enrolled a total of 214 symptomatic individuals with known COVID‐19 status using rRT‐PCR. We collected and tested paired nasopharyngeal (NP) and nasal swab (NS) specimens (collected from same individual) using rRT‐PCR and RATs (InTec and SD Biosensor). We assessed the performance of RATs considering specimen types, viral load, the onset of symptoms, and presenting symptoms. RESULTS: We included 214 paired specimens (112 NP and 100 NS SARS‐CoV‐2 rRT‐PCR positive) to the analysis. For NP specimens, the average sensitivity, specificity, and accuracy of the RATs were 87.5%, 98.6%, and 92.8%, respectively, when compared with rRT‐PCR. While for NS, the overall kit performance was slightly lower than that of NP (sensitivity 79.0%, specificity 96.1%, and accuracy 88.3%). We observed a progressive decline in the performance of RATs with increased Ct values (decreased viral load). Moreover, the RAT sensitivity using NP specimens decreased over the time of the onset of symptoms. CONCLUSION: The RATs showed strong performance under field conditions and fulfilled the minimum performance limit for rapid antigen detection kits recommended by World Health Organization. The best performance of the RATs can be achieved within the first week of the onset of symptoms with high viral load.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spreads rapidly worldwide, causing about 5 million deaths while writing this manuscript. During this prolonged COVID-19 pandemic, cost-effective rapid antigen tests (RATs) are warranted to detect SARS-CoV-2, especially in resource-limited settings. Currently, the real-time reverse transcription-polymerase chain reaction (rRT-PCR) is globally used and considered as the reference technique for detecting SARS-CoV-2 using nasopharyngeal (NP) swabs, throat swabs, nasal swab (NS), or saliva. [1] [2] [3] [4] However, rRT-PCR requires highly trained laboratory personnel and well-equipped laboratory facilities. Therefore, in a resource-limited setting, specimens required transportation to a laboratory with rRT-PCR capability. This transportation, along with a time-consuming rRT-PCR procedure, delays in delivering test results and increases the anxiety of the suspected COVID-19 patients. Also, this delay in test result delivery increases the risk of SARS-CoV-2 transmission, especially in densely populated areas. [5] [6] [7] The RAT using lateral flow principles have been introduced as quick and cost-effective methods to detect SARS-CoV-2 proteins.

The most important feature of these test kits is that they can be used as point-of-care (POC) diagnostic tools that require neither trained laboratory personnel nor well-equipped laboratory facilities.

These kits can increase the turn-around time for quick isolation of suspected cases in a remote and resource-limited area. Although the RAT is less sensitive than rRT-PCR, they can detect SARS-CoV-2 specimens of high viral load. [7] [8] [9] [10] [11] [12] Therefore, several countries approved these kits for mass screening. 13 Performance of RATs may vary depending on different influencing factors such as specimen type, quality of specimens, collection at the particular time point of disease progression, and viral load. For example, the sensitivity of SD Biosensor rapid SARS-CoV-2 antigen kits ranged from 75% to 98% in different settings. 14,15 World Health Organization (WHO) recommended that a RAT should show at least 80% sensitivity with clinical specimens. 16 Usually, NP specimens are recommended to detect respiratory viruses, including SARS-CoV-2, owing to their high sensitivity. 17 However, obtaining NP specimens are difficult than NS and often requires trained personnel to avoid neck injury. In contrast, NS specimens can be collected more rapidly and efficiently; this technique can also be used for the self-sampling method. Previous studies showed that SARS-CoV-2 could be detected in NS specimens at an early stage of infection; however, viral load and sensitivity of NS have been a concern. 18 The new RAT InTec Rapid SARS-CoV-2 Antigen Test (InTec PRODUCTS, INC., Fujian, P. R. China) was evaluated under field condition in Bangladesh. We compared the performance of this kit with the WHO recommended kit, Standard Q COVID-19 Ag (SD Biosensor, Korea), and gold standard rRT-PCR test.

A cross-sectional study of the diagnostic tests was designed to compare the performance of RATs with detect SARS-CoV-2 antigen. According to FDA, USA guideline, a minimum of 30 positive specimens and 30 negative specimens are required to evaluate each test. 19 Accordingly, we enrolled 214 COVID-19 symptomatic participants who fulfilled WHO case definitions for COVID-19 and who had known rRT-PCR test results within the last 24 h, using NP swab.

The criteria were as (i) all age group (ii) either sex; (iii) acute onset of fever or cough; OR (iv) acute onset of any three or more of the presented signs or symptoms, general weakness/fatigue, headache, myalgia, sore throat, runny nose, nasal congestion, dyspnea, anorexia/ nausea/vomiting, diarrhea, and altered mental status.

This study protocol was approved by the Institutional Review Board of icddr,b (PR-20146). We obtained signed informed consent from all study participants before specimen and data collection, and followed standard biosafety and biosecurity protocols during sample collection and transportation. The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

During May-August 2021, we collected 214 paired NP and NS specimens in a 1-ml viral transport media (VTM) for rRT-PCR and SD Biosensor and 200-µL buffer solution supplied with the InTec kit according to the manufacturer's instructions. We tested the specimens using rRT-PCR (following China CDC protocol), InTec (lot number: GJ21040477, Fujian, China), and SD Biosensor kits (lot number: QCO3020021C, Gyeonggi-do, South Korea), and the results were interpreted according to the manufacturers' guidelines. USA) was used. 21 We categorized all rRT-PCR-positive specimens as strong (Ct < 25), moderate (25) (26) (27) (28) (29) (30) , and weak (Ct > 30) positives.

COVID-19 cases were defined as either one NP or NS was positive by RT-PCR.

We calculated the sensitivity, specificity, and accuracy of the RATs with a 95% confidence interval (95% CI) using MedCalc online statistical software 22 using the following formula: 

Among 214 participants, 118 were male, mean age was 40.6 years (range 0.5 to 95.0), and median was 38.0. We considered several factors such as specimen type, viral load, different disease stages (days of symptom onset), and presenting symptoms to evaluate the rapid kit performances. We documented major symptoms of COVID-19 when the participants submitted specimens. Fever was identified in 88% of the participants while coughing, 78%; muscle aches, 45%; sore throat, 28%; runny nose, 48%; shortness of breath, 21%; headache, 56%; loss of appetite, 14%; vomiting, 12%; nausea, 20%; joint aches,17%; diarrhea, 17%; and altered smell, 27%.

Among 214 study participants, a total of 112 NP or NS specimens were COVID-19 positive by rRT-PCR. Both NP and NS specimens were positive for 100 cases, 112 was positive for NP only, and 100 was positive for NS only. The overall sensitivity of SD Biosensor was 84.8% (95% CI, 76.8 to 90.9), the specificity was 97.1% (95% CI, 91.6 to 99.4), and the accuracy was 90.7% (95% CI, 85.9 to 94.2) ( Table 1 ). The average sensitivity, specificity, and accuracy of the two RATs were 87.5%, 98.6%, and 92.8%, respectively.

Among 100 rRT-PCR-positive NS specimens, 80 (80%) and 78 (78%) were positive using InTec and SD Biosensor, respectively. Among 114 rRT-PCR-negative specimens, 3 and 6 were false positive using InTec and SD Biosensor, respectively. Thus, the overall sensitivity of InTec for NS was 80.0% (95% CI, 70.8 to 87.3), the specificity was 97.4% (95% CI, 92.5 to 99.5), and the accuracy was 89.6% (95% CI, 84.3 to 93.1) ( Table 1) . SD Biosensor kit showed the overall sensitivity was 78.0% (95% CI, 68.6 to 85.7), the specificity was 94.7% (95% CI, 88.9 to 98.0), and the accuracy was 86.9% (95% CI, 81.7 to 91.1).

The average sensitivity, specificity, and accuracy of the two RATs were 79.0%, 96.1%, and 88.3%, respectively.

The NP specimens showed significantly low Ct values than NS specimens (mean 21.5, SEM 0.61, median 19.9, SD 6.5 vs. mean 25.0, SEM 0.58, median 24.6, SD 5.8; p < 0.001), and several NP-positive specimens resulted in negative for NS (Figure 1 ). For NP, among strong positives (Ct < 25), the sensitivity of InTec was 98.8% (95% CI, 93.7 to 99.9) and SD Biosensor was 97.7% (95% CI, 91.9 to 99.7).

As for strong to moderate positives (Ct 25-30), the sensitivity of (Figure 1 ). In addition, we observed no remarkable difference in the performance of both RATs using NP and NS ( Figure 2 ).

We analyzed the performance of RATs using NP (112 positive and 102 negative) and NS (100 positive and 114 negative) specimens to evaluate clinical consequences over the performance.

We categorized the participants into three groups according to the onset of symptoms: 0-3 days (29, 13.6%), 4-7days (117, 54.7%), and >7 days (68, 31.7%) ( Table 2 ). Those who presented within 0-3 days were less likely to be positive than those between 4-7 days and >7 days using rRT-PCR. On the other hand, the sensitivity of InTec and SD Biosensor during 0-3 days was 100% compared with 96.6% vs. 89.8 during 4-7 days and 80.4% vs. 76.1% during >7 days using NP. As for NS, however, the highest sensitivity was observed for 4-7 days ( Table 2 ).

All study participants were symptomatic and presented different symptoms, as mentioned above. However, we did not find any significant association of symptoms with the sensitivity of the RATs (Supplementary Table ST1 ).

In this study, we evaluated the performance of the SARS-CoV-2 RATs, considering different influencing factors. The RATs showed TA B L E 1 Nasopharyngeal and nasal swab: rapid antigen kits vs rRT-PCR (RdRp) strong performance in field conditions. Three major factors, ie, specimen types, viral load (Ct values), and the onset of symptoms,

were identified as the influencing factors for the sensitivity of the RATs; however, we did not find any association of symptoms with the kit sensitivity.

The rRT-PCR quantitative values for NS were inconsistent, possibly due to uneven NS specimen collection. Therefore, both InTec and SD Biosensor RATs showed higher performance with NP specimens than NS specimens, which might be due to the low viral load in the NS specimen (relatively high Ct value).

Moreover, in the early stage of COVID-19 infections, we found high viral load (low Ct value), resulting in increased sensitivity of NP specimens (100% sensitivity) than NS (71% sensitivity). Thus, considering the specimen type, NP was found more sensitive than NS.

We found that both RATs showed high performance (>90% sensitivity) for lower Ct values (Ct ≤ 30). Previous studies showed that the rRT-PCR and other nucleic acid amplification tests (NAATs) were more sensitive than antigen tests to diagnose SARS-CoV-2, 23 which is inline with our findings where we found the relatively lower performance of RATs than rRT-PCR. However, the RATs (InTec and SD Biosensor) fulfilled the minimum performance limit for sensitivity (>80%) and specificity (>97%) set by WHO for the COVID-19 antigen test. 16 Considering only symptomatic cases for enrollment was a limitation of this study as asymptomatic individuals could carry SARS-CoV-2 and act as the silent killer by accelerating viral spread in the community. [24] [25] [26] Future studies should include asymptomatic populations and a more significant number of symptomatic cases with different times of symptom onset to observe the actual scenario.

Also, rapid kit evaluation using a specimen from the asymptomatic individual will provide more confidence to use this kit for mass screening in entry points such as airports, educational institutes, and offices. However, the rapid kits are Ct value-dependent; thus, the kits will also be effective for asymptomatic cases. 27, 28 Another individuals to reopen the office and educational institutes to limit the SARS-CoV-2 transmission. 

Interpreting diagnostic tests for SARS-CoV-2

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

Overview of Testing for SARS-CoV-2 (COVID-19)

Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection

Comparison of rapid antigen tests for COVID-19

Scaling up COVID-19 rapid antigen tests: promises and challenges

Liverpool COVID-19 community testing pilot: interim evaluation report summary

COVID-19: rapid antigen detection for SARS-CoV-2 by lateral flow assay: a national systematic evaluation for mass-testing. medRxiv

Put to the test: use of rapid testing technologies for covid-19

SARS-CoV-2 infectivity by viral load, S gene variants and demographic factors and the utility of lateral flow devices to prevent transmission. medRxiv

Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a cohort study

The accuracy of novel antigen rapid diagnostics for SARS-CoV-2: a living systematic review and meta-analysis. medRxiv

Rapid SARS-CoV-2 antigen detection assay in comparison with real-time RT-PCR assay for laboratory diagnosis of COVID-19 in Thailand

Clinical evaluation of SARS-CoV-2 antigen-based rapid diagnostic test kit for detection of COVID-19 cases in Bangladesh

Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays.; 2020.Interim guidance 2020 World Health Organization

Comparison of respiratory specimen collection methods for detection of influenza virus infection by reverse transcription-PCR: a literature review

Detection of SARS-CoV-2 in nasal swabs: Comparison with nasopharyngeal swabs

Policy for coronavirus disease-2019 tests during the public health emergency (revised)

Three novel real-time RT-PCR assays for detection of COVID-19 virus

A Case Series Describing the Recurrence of COVID-19 in Patients Who Recovered from Initial Illness in Bangladesh

MedCalc: a new computer program for medical statistics

Nucleic Acid Amplification Tests (NAATs)

Coronavirus disease 2019-COVID-19

The natural history, pathobiology, and clinical manifestations of SARS-CoV-2 infections

Clinical course and molecular viral shedding among asymptomatic and symptomatic patients with SARS-CoV-2 infection in a community treatment center in the Republic of Korea

Performance evaluation of a lateral flow assay for nasopharyngeal antigen detection for SARS-CoV-2 diagnosis

Time scale performance of rapid antigen testing for SARS-COV-2: evaluation of ten rapid antigen assays. medRxiv

Comparative performance of SARS-CoV-2 lateral flow antigen tests and association with detection of infectious virus in clinical specimens: a single-centre laboratory evaluation study. The Lancet Microbe